<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; under</title>
	<atom:link href="http://www.tapanray.in/tag/under/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Will the ‘Bayer–Cipla case’ now put the ‘Bolar Provision’ under judicial scrutiny?</title>
		<link>http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny</link>
		<comments>http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/#comments</comments>
		<pubDate>Thu, 22 Oct 2009 01:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[Bayer–Cipla]]></category>
		<category><![CDATA[Bolar]]></category>
		<category><![CDATA[Case]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[judicial]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[now]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Provision]]></category>
		<category><![CDATA[put]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[under]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=748</guid>
		<description><![CDATA[To enable the domestic pharmaceutical industry gaining a critical mass and cater to the pressing healthcare needs of the nation, in 1970 product patent act was abolished by the government of India. This immensely helped the domestic companies to launch &#8230; <a href="http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-the-bayer-cipla-case-now-put-the-bolar-provision-under-judicial-scrutiny/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Revised Mashelkar Committee Report recommends inclusion of ‘incremental innovation’ under patentability criteria.</title>
		<link>http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria</link>
		<comments>http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/#comments</comments>
		<pubDate>Sun, 26 Apr 2009 09:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compliant]]></category>
		<category><![CDATA[criteria]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Mashelkar]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recommends]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Revised]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[under]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=906</guid>
		<description><![CDATA[In 2006, the Government of India appointed a Technical Expert Group (TEG) chaired by the eminent scientist and the then Director General of the Council of Scientific and Industrial Research (CSIR) Dr. R.A. Mashelkar, with the following terms of reference:1. &#8230; <a href="http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/revised-mashelkar-committee-report-recommends-inclusion-of-incremental-innovation-under-patentability-criteria/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
